Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6527466 | 1.00 | PTGDR2 (0.38) | PTGDR2ENPP2LOXL2POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5846745 | 0.99 | PTGDR2 (0.37) | PTGDR2ENPP2LOXL2POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5846749 | 0.99 | PTGDR2 (0.37) | PTGDR2ENPP2LOXL2POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6527463 | 0.99 | PTGDR2 (0.37) | PTGDR2ENPP2LOXL2POLBSMN1; SMN2 | |
| SCHEMBL6531275 | 0.84 | SMN1; SMN2 (0.56) | PTGDR2SMN1; SMN2TSHR | |
| SCHEMBL6531271 | 0.84 | SMN1; SMN2 (0.56) | PTGDR2SMN1; SMN2TSHR | |
| SCHEMBL5848110 | 0.82 | STING1 (0.42) | PTGDR2POLBSMN1; SMN2 | |
| SCHEMBL5848117 | 0.82 | STING1 (0.42) | PTGDR2POLBSMN1; SMN2 | |
| SCHEMBL5848113 | 0.82 | STING1 (0.42) | PTGDR2POLBSMN1; SMN2 | |
| SCHEMBL23705293 | 0.80 | ADRA2A (0.42) | PTGDR2SMN1; SMN2NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034051-B2 | Fused bicyclic carboxamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1 | PTGDR2 1500/4885ENPP2 1342/4885LOXL2 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.